Study outcomes
HCM
REGRESSION, LV HYPERTROPHY, RECRUITMENT
The primary objective is to determine whether trientine compared with placebo leads to regression of LV hypertrophy. The primary outcome measure is change in LVMi (g/mThe trial is also evaluating the safety of trientine in HCM and whether treatment effect varies according to genotype. Screening and recruitment data and clinical endpoints are recorded to inform a subsequent phase III trial. Consent is requested to enable long-term follow-up using routinely collected healthcare data with appropriate linkage.